OncoAlly® Cancer Predisposition

OA010

OncoAlly® Cancer Predisposition uses a whole genome sequencing platform to analyze 120 genes for genetic variants associated with hereditary cancers.

Test Description

OncoAlly® Cancer Predisposition uses a whole genome sequencing platform to analyze 120 genes for genetic variants associated with hereditary cancers.

*This is an optional analysis when ordering OncoAlly® Solid Tumor Analysis.

When to Order

Order this test when a patient has a medical or family history suggestive of one or more hereditary cancer predisposition syndromes or when germline variant analysis for hereditary cancer predisposition is necessary to guide medical management.

Included Analyses

  • Sequence analysis of hereditary cancer-associated genes (single nucleotide variants, deletions, insertions, and characterized intronic variants)
  • Copy number variant analysis of hereditary cancer-associated genes (duplications/deletions, mobile element insertions, and inversions)

Included Genes

ABRAXAS1, ACD, ALK, APC, ATM, ATR, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, BUB1B, CDC73, CDH1, CDK4, CDKN1B, CDKN2A, CEBPA, CHEK2, CLDN2, CPA1, CSF3R, CTNNA1, CTRC, CTR9, DDX41, DICER1, DIS3L2, EGFR, EGLN1, ELP1, EPCAM, ERBB2, ETV6, FH, FLCN, FOCAD, GALNT12, GATA2, GPC3, GREM1, GSKIP, HOXB13, HRAS , IKZF1, KIF1B, KIT, LZTR1, MAX, MBD4, MC1R, MEN1, MET, MITF, MLH1, MLH3, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PAX5, PDGFRA, PHOX2B, PMS2, POLD1, POLE, POT1, PRKAR1A, PRSS1, PTCH1, PTEN, PTPN11, RAD51C, RAD51D, RB1, RECQL4, RET, RHBDF2, RNASEL, RNF43 , RPL5, RPS20, RUNX1, SAMD9, SAMD9L, SDHA, SDHAF2, SDHB, SDHC, SDHD, SLC25A11, SMAD4, SMARCA4, SMARCB1, SMARCE1, SOS1, SPINK1, SRP72, STK11, SUFU, TERC, TERF2IP, TERT, TMEM127, TP53, TRIM28, TRIP13, TSC1, TSC2, VHL, WRN, WT1

View a list of cancers associated with each gene.

Turnaround Time

A report will be issued concurrently with the OncoAlly® Solid Tumor Analysis report, within 14 days from receipt of required samples.

Sample Types

CPT Codes

81162, 81432, 81433, 81435, 81436, 81479

The CPT codes provided are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

Methods and Limitations

OncoAlly® Cancer Predisposition Analysis uses a PCR-free whole genome sequencing (WGS) platform paired with our Genomic Intelligence® analytical software.

SNVs:
99.9% sensitivity
99.9% specificity
99.8% positive predictive value

Structural variants:
96% clinical sensitivity

Test limitations:
The PMS2 gene contains regions that are non-unique, therefore not all variants can be assigned to the correct location, limiting interpretation.

The VHL gene is not fully covered by this test, therefore there may be variants in certain regions of this gene that are not identified.